6-氯-5-甲基吡啶-2-羧酸 | 1166828-13-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 6-氯-5-甲基吡啶-2-羧酸
• 英文名称: 6-chloro-5-methylpyridine-2-carboxylic acid
• CAS: 1166828-13-2
• 化学式: C₇H₆ClNO₂
• 分子量: 171.583
• InChiKey: ZURJURQGGWNOFN-UHFFFAOYSA-N

物化性质

• 沸点：
  346.2±37.0 °C(Predicted)
• 密度：
  1.390±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  50.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 6-Chloro-5-methylpyridine-2-carboxylic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 6-Chloro-5-methylpyridine-2-carboxylic acid
CAS number: 1166828-13-2

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H6ClNO2
Molecular weight: 171.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  6-氯-5-甲基吡啶-2-羧酸 在 盐酸 、 sodium sulfite 作用下， 以 1,4-二氧六环 、 乙醇 、 水 为溶剂， 反应 4.0h， 生成 5-methyl-6-sulfo-pyridine-2-carboxylic acid methyl ester
  参考文献：
  名称：

  [EN] PYRIDIN- 2 -AMIDES USEFUL AS CB2 AGONISTS
  [FR] PYRIDIN-2-AMIDES UTILES COMME AGONISTES DE CB2

  摘要：

  本发明涉及式(I)的化合物，其中R1至R4的定义如描述和权利要求中所述。式(I)的化合物可以用作药物。

  公开号：

  WO2012168350A1
• 作为产物：
  描述：

  5-甲基-2-甲酸吡啶 在 间氯过氧苯甲酸 、 三氯氧磷 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 生成 6-氯-5-甲基吡啶-2-羧酸
  参考文献：
  名称：

  [EN] PYRIDIN- 2 -AMIDES USEFUL AS CB2 AGONISTS
  [FR] PYRIDIN-2-AMIDES UTILES COMME AGONISTES DE CB2

  摘要：

  本发明涉及式(I)的化合物，其中R1至R4的定义如描述和权利要求中所述。式(I)的化合物可以用作药物。

  公开号：

  WO2012168350A1

文献信息

• [EN] CARBAMOYL COMPOUNDS AS DGAT1 INHIBITORS 190<br/>[FR] COMPOSÉS CARBAMOYLES COMME INHIBITEURS DE DGAT1 190
  申请人：ASTRAZENECA AB

  公开号：WO2009081195A1

  公开（公告）日：2009-07-02

  DGAT-1 inhibitor compounds of formula (I), pharmaceutically-acceptable salts and pro- drugs thereof are described, together with pharmaceutical compositions, processes for making them and their use in treating, for example, obesity wherein, for example, Ring A is optionally substituted 2,6-pyrazindiyl; X is =O; Ring B is optionally substituted 1,4-phenylene; Y1 is a direct bond or -O-; Y2 is -(CH 2) r- wherein r is 2 or 3; n is 0 or n is 1 when Y1 is a direct bond between Ring B and Ring C and when Ring B is 1,4-phenylene and Ring C is (4-6C)cycloalkane; Ring C is optionally substituted (4-6C)cycloalkane, (7-10C)bicycloalkane, (8-12C)tricycloalkane, phenylene or pryidindiyl; L is a direct bond or -O-; p is 0, 1 or 2 and when p is 1 or 2 RA1 and RA2 are each independently hydrogen or (1-4C)alkyl; Z is carboxy or a mimic or bioisostere thereof.

  DGAT-1抑制剂化合物公式(I)，药用可接受的盐和前药，以及药物组合物、制造它们的过程以及它们在治疗例如肥胖症中的用途，其中，例如，环A是可选取代的2,6-吡嗪二基；X是=O；环B是可选取代的1,4-苯基；Y1是直接键或-O-；Y2是-(CH2)r-，其中r是2或3；n是0或当Y1是环B和环C之间的直接键并且当环B是1,4-苯基和环C是(4-6C)环烷时，n是1；环C是可选取代的(4-6C)环烷、(7-10C)双环烷、(8-12C)三环烷、苯基或吡啶二基；L是直接键或-O-；p是0、1或2，并且当p是1或2时，RA1和RA2各自独立地为氢或(1-4C)烷基；Z是羧酸或其模拟物或生物等排体。
• NOVEL PYRIDINE DERIVATIVES
  申请人：Bissantz Caterina

  公开号：US20120316147A1

  公开（公告）日：2012-12-13

  The invention relates to a compound of formula (I) wherein R 1 to R 4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.

  本发明涉及一种公式(I)的化合物 其中R1至R4定义如描述和权利要求中所述。公式(I)的化合物可作为药物使用。
• [EN] INDAZOLE COMPOUNDS AS IRAK4 INHIBITORS<br/>[FR] COMPOSÉS D'IMIDAZOLE UTILISABLES EN TANT QU'INHIBITEURS DE L'IRAK4
  申请人：AURIGENE DISCOVERY TECH LTD

  公开号：WO2015104662A1

  公开（公告）日：2015-07-16

  The present invention provides indazole compound of formula (I), which are therapeutically useful as kinase inhibitor, particularly IRAK4 inhibitors. wherein Z1, Z2, R1, R2, R3, 'm' and 'n' have the meanings given in the specification, and pharmaceutically acceptable salts or stereoisomers thereof that are useful in the treatment and prevention of diseases or disorder, in particular their use in diseases or disorder mediated by kinase enzyme, particularly IRAK4 enzyme. The present invention also provides pharmaceutical composition comprising at least one of the compounds of compound of formula (I) together with a pharmaceutically acceptable carrier, diluent or excipient therefor.

  本发明提供了式（I）的吲唑化合物，其在治疗中具有潜在的激酶抑制作用，特别是IRAK4抑制剂。其中Z1、Z2、R1、R2、R3、'm'和'n'的含义如规范中所述，并且其药学上可接受的盐或立体异构体在治疗和预防疾病或紊乱方面具有用处，特别是在由激酶酶介导的疾病或紊乱中的应用，特别是IRAK4酶。本发明还提供了包括至少一种式（I）化合物的药物组合物，以及药学上可接受的载体、稀释剂或赋形剂。
• Indazole Compounds as IRAK4 Inhibitors
  申请人：AURIGENE DISCOVERY TECHNOLOGIES LIMITED

  公开号：US20160326151A1

  公开（公告）日：2016-11-10

  The present invention provides indazole compounds of formula (I), which are therapeutically useful as kinase inhibitors, particularly IRAK4 inhibitors, wherein Z 1 , Z 2 , R 1 , R 2 , R 3 , ‘m’ and ‘n’ have the meanings given in the specification, and pharmaceutically acceptable salts or stereoisomers thereof that are useful in the treatment and prevention of diseases or disorders, in particular their use in diseases or disorders mediated by kinase enzyme, particularly IRAK4 enzyme. The present invention also provides pharmaceutical compositions comprising at least one of the compounds of the compound of formula (I) together with a pharmaceutically acceptable carrier, diluent or excipient.

  本发明提供了式（I）的吲唑化合物，作为激酶抑制剂在治疗上具有疗效，特别是IRAK4抑制剂，其中Z1、Z2、R1、R2、R3、'm'和'n'在规范中给出了含义，并且其药学上可接受的盐或立体异构体在治疗和预防疾病或疾病中有用，特别是它们在由激酶酶介导的疾病或疾病中的使用，特别是IRAK4酶。本发明还提供了包括至少一种式（I）化合物的药物组合物，以及药学上可接受的载体、稀释剂或赋形剂。
• ALKYNYL ALCOHOLS AND METHODS OF USE
  申请人：Genentech, Inc.

  公开号：US20150057260A1

  公开（公告）日：2015-02-26

  The invention relates to compounds of Formula (0): wherein A 1 -A 8 , R 4 and R 5 each has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.

  该发明涉及具有以下结构的化合物（0）：其中A1-A8，R4和R5分别具有如本文所述的含义。 公式（0）的化合物及其药物组成物在治疗观察到NF-kB信号不受欢迎或过度激活的疾病和紊乱中是有用的。